Australia Markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
77.49+0.41 (+0.53%)
As of 12:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close77.08
Bid77.45 x 1000
Ask77.52 x 1100
Day's range77.09 - 78.53
52-week range12.52 - 105.00
Avg. volume2,954,171
Market cap18.456B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings date12 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est76.15
  • GlobeNewswire

    BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020

    MAINZ, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August 11th, 2020. BioNTech will also host a conference call and webcast on the same day at 08:00 a.m. EDT (2:00 p.m. CEST) to report its financial results and provide a corporate update on the second quarter 2020. The slide presentation and audio of the webcast will be available via the following link: participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:United States international:+1 646 741 3167 United States domestic (toll-free):+1 877 870 9135 Germany:+49 (0) 692 2222 625 Conference ID:1963889 Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.About BioNTech Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.For more information, please visit Contacts:Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 Media@biontech.deInvestor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074

  • BioNTech (BNTX) to Report Q2 Earnings: What's in Store?

    BioNTech (BNTX) to Report Q2 Earnings: What's in Store?

    During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.

  • The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech

    The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech

    The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech